Índice de contenidos
  1. OBJETIVOS DOCENTES DEL MÓDULO 3
  2. 1. INTRODUCCIÓN
  3. 2. CONCEPTOS GENERALES
  4. 3. PRINCIPALES POLIMORFISMOS QUE AFECTAN A LAS ENZIMAS
    1. 3.1. Polimorfismos de los citocromos del P450
      1. 3.1.1. Polimorfismos del CYP3A
        1. 3.1.1.1. Importancia de los polimorfismos del CYP3A5
      2. 3.1.2. Polimorfismos del CYP2D6
        1. 3.1.2.1. Importancia de los polimorfismos del CYP2D6
      3. 3.1.3. Polimorfismos del CYP1A2
      4. 3.1.4. Polimorfismos del CYP2C9
        1. 3.1.4.1. Importancia de los polimorfismos del CYP2C9
      5. 3.1.5. Polimorfismos del CYP2C8
      6. 3.1.6. Polimorfismos del CYP2C19
        1. 3.1.6.1. Importancia de los polimorfismos del CYP2C19
      7. 3.1.7. Polimorfismos de otros CYP
    2. 3.2. METABOLISMO DE FÁRMACOS POR LAS ENZIMAS DE FASE II
      1. 3.2.1. Polimorfismos de la Glutation S-Transferasa (GST)
      2. 3.2.2. Polimorfismos de la N-Acetil-Transferasa (NAT)
      3. 3.2.3. Polimorfismos de la UDP-Glucuroniltransferasa (UGT)
    3. 3.3. POLIMORFISMOS DE LOS TRANSPORTADORES DE FÁRMACO
      1. 3.3.1. Polimorfismos del MDR1
        1. 3.3.1.1. Importancia de los polimorfismos del MDR1
  5. 4. FUTURO DE LA FARMACOGENÉTICA
  6. 5. CASO CLÍNICO
  7. 6. BIBLIOGRAFÍA
Descargar curso en PDF
Módulo 3
Profesor
José Cristian Plaza Plaza
Módulo 3
◄ anterior

6. BIBLIOGRAFÍA

1 Wilkinson G. Drug Metabolism and Variability among Patients in Drug Response. N Engl J Med. 2005; 352: 2211-21.

2 Lazarou J, Pomeranz BH, Corey PN. Incidente of adverse drug reactions in hospitalizad patients: a meta-analysis of prospectives studies. JAMA. 1998; 279: 1200-1205.

3 Dipiro J, Wells B. Pharmacotherapy: A pathophisiologyc approach. 5a Edición. MC Graw-Hill, 2005.

4 Alving AS, Carson PE, Flanagan CL, Ickes CE. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science. 1956; 124: 484–485.

5 Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999; 353: 717–719.

6 Drozdzik M, Bialecka M, Mysliwiec K, Honczarenko K, Stankiewicz J, Sych Z. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics. 2003, 13(5): 259-263.

7 Vogel F. Modern problems of human genetics. Ergeb Inn Med Kinderheilkd. 1959; 12: 52-125.

8 Gelehrter TD, Collins FS, Ginsburg DG. Principles of Medical Genetics. 2nd Edición. Baltimore: Williams & Wilkins; 1998: 341-350.

9 Oak Ridge National Laboratory. Human Project Information. www.ornl.gov/sci/techresources/Human_Genome/home.shtml.

10 International HapMap. www.hapmap.ncbi.nlm.nih.gov.

11 Redon R, Ishikawa S, Fitch KR et al. Global variation in copy number in the genome. Nature. 2006; 444:444-454.

12 Frueh FW, Amur S, Mummaneni P et al. Pharmacogenomic biomarker information in drug labels approved by the United States Food and Drug Administration: prevalence of related drug use. Pharmacotherapy. 2008; 28:992-998.

13 Guengerich F. Cytochromes P450, Drugs, and Diseases. Molecular Interventions, 2003; 3:194-204.

14 Randic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducer, and inhibitors. Drug Metab Rev. 1997; 29(1-2): 413-580.

15 Bertz R. J., & Granneman G. R. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet. 1997; 32: 210-258.

16 Floyd M. D., Gervasini G., Masica A. L., Mayo G., George A. L., Jr. Bhat K. et al. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics. 2003; 13: 595-606.

17 Ozdemir V., Kalowa W., Tang B. K., Paterson A. D., Walker S. E., Endrenyi L. et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics. 2000; 10: 373-388.

18 Hustert E., Haberl M., Burk O., Wolbold R., He Y. Q., Klein K., et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics. 2001; 11:773-779.

19 Lee S. J., Usmani K. A., Chanas B., Ghanayem B., Xi T., Hodgson E., et al. Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics. 2003; 13: 461-472.

20 Macphee I. A., Fredericks S., Mohamed M., Moreton M., Carter N. D., Johnston A., et al. Tacrolimus pharmacogenetics: the CYP3A51 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. Transplantation. 2005; 79: 499-502.

21 Tada H., Tsuchiya N., Satoh S., Kagaya H., Li Z., Sato K., et al. Impact of CYP3A5 and MDR1 (ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplant Proc. 2005; 37: 1730-1732.

22 Min D. I., & Ellingrod V. L. Association of the CYP3A4*1B 5'-flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit. 2003; 25: 305-309.

23 Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet. 1989; 45: 889-904.

24 Wennerholm A., Johansson I., Hidestrand M., Bertilsson L., Gustafsson L. L., & Ingelman-Sundberg M. Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity. Pharmacogenetics. 2001; 11: 417-427.

25 Bertilsson L, Dahl M-L, Dalén P, Al- Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol. 2002; 53 :111-122.

26 Lessard E, Yessine MA, Hamelin BA, O’Hara G, LeBlanc J, Turgeon J. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics.1999; 9: 435-443.

27 Kaneda Y, Kawamura I, Fuji a; Ohmoti T. Serotonine Syndrome –“potencial” role of the CYP2D6 genetic polymorphism in Asians. Int J Neuropsychopharmacol.2002; 5(1): 105-106.

28 Farin FM, Omiecinski CJ. Regioespecific expression of cytochrome P-450 and microsomal epoxide hydrolase in human brain tissue. J Toxicol Environ Health. 1993; 40(2-3): 317-335.

29 Eckhardt K, Ammon S, Schanzie G, Mikus G, Eichenlbaum M. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain. 1998; 76(1-2): 27-33.

30 Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med. 2004. 30; 351(27):2827-31.

31 Jin Y, Desta Z, Stearns V et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005; 97:30-39.

32 Goetz MP, Knox SK, Suman VJ et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007; 101:113-121.

33 Guengerich F. Cytochromes P450, Drugs, and Diseases. Molecular Interventions, 2003; 3: 194-204.

34 Sachse C., Brockmoller J., Bauer S., & Roots I. Functional significance of a C>A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol. 1999; 47: 445-449.

35 Schwarz U. I. Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur J Clin Investig. 2003; 33(Suppl 2): 23-30.

36 Kirchheiner J., Nickchen K., Bauer M., Wong M. L., Licinio J., Roots I., et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004; 9: 442-473.

37 Kirchheiner J., Roots I., Goldammer M., Rosenkranz B., & Brockmoller J. Effect of genetic polymorphisms in cytochrome P450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet. 2005; 44: 1209-1225.

38 Daly AK, King BP. Pharmacogenetics of oral anticoagulants. Pharmacogenetics. 2003; 13: 247-52.

39 Higashi M. K., Veenstra D. L., Kondo L. M., Wittkowsky A. K., Srinouanprachanh S. L., Farin F. M., et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002; 287:1690-1698.

40 Rieder MJ, Reiner AP, Gage BF et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005; 352: 2285-2293.

41 Wadelius M., Chen L. Y., Eriksson N., Bumpstead S., Ghori J., Wadelius C., et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet. 2007; 121: 23-34.

42 Bodin et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood. 2005 Jul 1; 106(1):135-40.

43 Lundblad M. S., Stark K., Eliasson E., Oliw E., & Rane A. Biosynthesis of epoxyeicosatrienoic acids varies between polymorphic CYP2C enzymes. Biochem Biophys Res Commun. 2005; 327: 1052-1057.

44 Soyama A., Saito Y., Hanioka N., Murayama N., Nakajima O., Katori N. et al. Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism. Biol Pharm Bull. 2001; 24: 1427-1430.

45 Ishikawa C., Ozaki H., Nakajima T., Ishii T., Kanai, S., Anjo S., et al. A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin. J Hum Genet. 2004; 49: 582-585.

46 Dal, D., Zeldin D.C., Blasdell J.A., Chanas B., Coulter S.J., Ghanayem B.I., Goldstein J.A. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachedonic acid. Pharmacogenetics. 2001; 11(7): 597-607.

47 Niemi M., Backman J. T., Kajosaari L. I., Leathart J. B., Neuvonen M., Daly A. K. et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther. 2005; 77: 468-478.

48 Desta Z., Zhao X., Shin J. G., & Flockhart D. A. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002; 41: 913-958.

49 Kawamura M., Ohara S., Koike T., Iijima K., Suzuki H., Kayaba S. et al. Cytochrome P450 2C19 polymorphism influences the preventive effect of lansoprazole on the recurrence of erosive reflux esophagitis. J Gastroenterol Hepatol. 2007; 22: 222-226.

50 Furuta T, Shirai N, Takashima M, et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther. 2001; 69:158-68.

51 Pemble S., Schroeder K.R., Spencer S.R., Meyer D.J., Hallier E., Bolt H.M., Ketterer B., Taylor J.B. Human glutatione S-Transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J. 1994; 300(Pt 1): 271-276.

52 Andonova IE, Sarueva RB, Horvath AD, Simeonov VA, Dimitrov PS, Petropoulos EA, Ganev VS. Balkan endemic nephropathy and genetic variants of glutathione S-transferases. J Nephrol. 2004; 17 (3): 390-8.

53 Andonova IE, Sarueva RB, Horvath AD, Simeonov VA, Dimitrov PS, Petropoulos EA, Ganev VS. Balkan endemic nephropathy and genetic variants of glutathione S-transferases. J Nephrol. 2004; 17 (3): 390-8.

54 Bosma P.J., Chowdhury J.R. Bakker C., Gantia S., de Boer A., Oostra B.A., Lindhout D., Tytgar G.N., Jansen P.L., Oude Elferink R.P., et al.

55 Germann UA. P-glycoprotein: a mediator of multidrug resistance in tumor cells. Eur J Cancer. 1996; 32A: 927-44.

56 Mickley LA., Lee J.S., Weng Z., et al. Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood 1998; 91: 1749-56.

57 Hoffmeyer S, Burk O., von Richter O. et al. Functional polymor phisms of the human multidrug-resistance gene: multiple sequence variants and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000; 97: 3473-8.

58 Furuno T., Landi M.T., Ceroni M., et al. Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics 2002; 12: 529-34.

59 Siegsmund M, Brinkmann U, Scháffeler E, Weirich G, Schwab M, Eichelbaum M, Fritz P, Burk O, Decker J, Alken P, Rothenpieler U, Kerb R, Hoffmeyer S, Brauch H. Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol. 2002; 13 (7):1847-1854.

60 Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, Retelska D, Ruiz L, Schinkel AH, Vernazza P, Eap CB, Telenti A. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet. 2002; 359(9300): 30-36.

61 Johne A, Kopke K, Gerloff T, et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther. 2002; 72: 584-94.

62 Kurata Y, Ieiri I, Kimura M, et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther.2002; 72: 209-29.